<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NWS6QFW" height="0" width="0" style="display:none;visibility:hidden">

Sandra Acosta

Sandra Acosta
Sandra Acosta has over 30 years of experience in the pharmaceutical and biotechnology industries. Her expertise ranges across areas such as project management, engineering/validation, compliance/regulatory, and sterile processes, on an international scale. In 1995 she created, managed, and directed BioWell, a specialized microbiology laboratory that served international pharmaceutical and biotechnology companies and agencies. Most recently, as a project manager, Sandra led a team across multiple workstreams for a site remediation project at a global biopharma company. In her role as Director of Biopharma Solutions, Sandra is responsible for the creation and support of client solutions on many levels, from launching projects and providing ongoing oversight and direction, to assessing and engaging talent. Sandra is an instrumental part in leading the expanded delivery of positive outcomes and deliverables to clients. In her role as a PMO, Sandra also led additional efforts on the redesign of the sterile process for the novel COVID-19 vaccine production for commercial purposes.
Find me on:

Recent Posts

Behind the Scenes: The Production of Viral Vector Vaccines

Posted by Sandra Acosta

As shared in our previous blog post, "Cell Gene Therapy and Viral Vectors," the making of a vaccine is a complex process that requires extensive knowledge and expertise to minimize all potential risks that could be a threat to human life. The vaccine industry used to be relatively small, but due to recent events, there is more demand for expertise in the field.

Read More »

What are Viral Vectors and How Do They Work?

Posted by Sandra Acosta

As shared in our previous blog posts about the vaccine industry and cell gene therapy, the making of a vaccine is a complex process that requires extensive knowledge and expertise to minimize all potential risks that could be a threat to human life. The vaccine industry used to be relatively small, but due to COVID-19, the industry has only grown.

Read More »

Cell Gene Therapy and Viral Vectors: How Can They Be Effective for Compromising Diseases and COVID-19?

Posted by Sandra Acosta

Who would have thought that genes and cells can be manipulated in such a way to treat and cure compromising diseases? Cell gene therapies, also known as monoclonal treatment, have brought a new era in the biotech industry as a way of treatment for many compromising diseases like cancer, diabetes, genetic disorders, blindness, muscular dystrophy, and even Alzheimer’s. Now, these therapies are aiming to treat COVID-19.

Read More »

Viral Controls and Prevention of Cross-Contamination in the Vaccine Industry

Posted by Sandra Acosta

Cross-contamination is a potential risk within the vaccine manufacturing process, especially if different products are processed in the same controlled rooms. Cross-contamination can occur if required controls are not in place to eliminate risks that could impact product quality and, most of all, compromise human lives.

Miss the first post in the series? Read "Sources of Cross-Contamination in Vaccine Production"

Read More »

Sources of Cross-Contamination in Vaccine Production

Posted by Sandra Acosta

As more vaccines for COVID-19 emerge, safety in the vaccine production process is crucial. Any foreign matter entering the vaccine production process raises major safety concerns, and contamination is a common occurrence and a public health risk.

All of us who work in the Biotech industry or the pharmaceutical industry, including those of us at EG Life Sciences, face daily challenges to maintain an aseptic environment. Rigorous safety standards are in place to avoid any cross-contamination and/or any foreign matter being introduced to the vaccine production process. However, there is still a chance that this could happen.

Read More »

Subscribe to our Blog

Popular Posts

Popular Posts